INOVIQ Ltd Stock

Equities

IIQ

AU0000196149

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:42:56 2024-04-26 EDT 5-day change 1st Jan Change
0.525 AUD -1.87% Intraday chart for INOVIQ Ltd -0.94% -21.05%

Financials

Sales 2024 * 1.6M 1.05M 1.43M Sales 2025 * 6.4M 4.18M 5.71M Capitalization 48.31M 31.56M 43.1M
Net income 2024 * -8M -5.23M -7.14M Net income 2025 * -5M -3.27M -4.46M EV / Sales 2024 * 25.8 x
Net cash position 2024 * 7.1M 4.64M 6.33M Net cash position 2025 * 9.4M 6.14M 8.39M EV / Sales 2025 * 6.08 x
P/E ratio 2024 *
-5.65 x
P/E ratio 2025 *
-11.7 x
Employees 15
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.87%
1 week-0.94%
Current month-13.93%
1 month-10.26%
3 months+0.96%
6 months-12.50%
Current year-21.05%
More quotes
1 week
0.53
Extreme 0.525
0.56
1 month
0.53
Extreme 0.525
0.72
Current year
0.50
Extreme 0.495
0.92
1 year
0.47
Extreme 0.465
0.99
3 years
0.39
Extreme 0.385
3.50
5 years
0.39
Extreme 0.385
5.60
10 years
0.18
Extreme 0.18
5.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 16-11-06
Director of Finance/CFO - 22-11-01
Chief Tech/Sci/R&D Officer - 21-09-19
Members of the board TitleAgeSince
Chairman 70 11-28
Director/Board Member 65 19-06-17
Director/Board Member - 20-07-27
More insiders
Date Price Change Volume
24-04-26 0.525 -1.87% 24,001
24-04-24 0.535 +0.94% 8,037
24-04-23 0.53 0.00% 101,725
24-04-22 0.53 0.00% 68,140
24-04-19 0.53 -17.19% 658,199

Delayed Quote Australian S.E., April 26, 2024 at 01:42 am

More quotes
INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.
More about the company

Annual profits - Rate of surprise